Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Tau accumulation in patients with Alzheimer’s disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. This phase 2 study evaluated the safety and efficacy of tilavonemab, an anti-tau monoclonal antibody, in patients with early Alzheimer’s disease. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Florian, Hana, Wang, Deli, Arnold, Steven E, Boada, Mercè, Guo, Qi, Jin, Ziyi, Zheng, Hui, Fisseha, Nahome, Kalluri, Hari Varun, Rendenbach-Mueller, Beatrice, Budur, Kumar, Gold, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232284/
https://www.ncbi.nlm.nih.gov/pubmed/36730056
http://dx.doi.org/10.1093/brain/awad024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232284/
https://www.ncbi.nlm.nih.gov/pubmed/36730056
http://dx.doi.org/10.1093/brain/awad024

Ejemplares similares